• About Us
  • Contact Us
  • Today Headline
  • Write for us
Today Headline
No Result
View All Result
  • breaking news today
    • Politics news
    • Sports
    • Science News & Society
  • Entertainment News
    • Movie
    • Gaming
  • Technology News
    • Automotive
  • Health News
    • Lifestyle
    • Insurance
  • Finance News
    • Money
  • Enterprise
  • Contact Us
  • breaking news today
    • Politics news
    • Sports
    • Science News & Society
  • Entertainment News
    • Movie
    • Gaming
  • Technology News
    • Automotive
  • Health News
    • Lifestyle
    • Insurance
  • Finance News
    • Money
  • Enterprise
  • Contact Us
No Result
View All Result
TodayHeadline
No Result
View All Result

Pfizer slashes 2022 earnings outlook despite strong first quarter Covid vaccine and antiviral sales – CNBC

May 3, 2022
in breaking news today
Reading Time: 3 mins read
nmprofetimg 290 - TodayHeadline

Albert Bourla, chief executive officer of Pfizer pharmaceutical company, arrives to ring the closing bell at the New York Stock Exchange.

Drew Angerer | Getty Images

Pfizer on Tuesday cut its 2022 earnings guidance, despite reporting first quarter results that beat on the top and bottom line due to strong Covid vaccine and antiviral sales.

The pharmaceutical giant now expects earnings per share of $6.25 to $6.45 per share for the year, down from its previous outlook of $6.35 to $6.55 per share. Pfizer attributed its lower earnings guidance to research and development costs and changes in foreign exchange rates. However, the company is still projecting $98 billion to $102 billion in total sales for 2022.

Pfizer stock was flat in early morning trading.

The company’s first quarter revenue grew 77% to more than $25 billion compared to the same period last year, driven by $13.2 billion in Covid vaccine sales in the quarter and $1.5 billion in sales of its oral antiviral treatment Paxlovid.

Pfizer booked a net income of $7.8 billion, a 61% increase over the first quarter of 2021. Adjusted first-quarter earnings grew 72% to $1.62 per share compared to the same period last year.

Here’s how the company performed compared to what Wall Street expected for the first quarter, based on analysts’ average estimates compiled by Refinitiv:

  • Adjusted EPS: $1.62 per share, vs. $1.47 expected
  • Revenue: $25.66 billion, vs. $23.86 billion expected

Pfizer said booster doses and shots for children drove its Covid vaccine revenue in the quarter. Paxlovid sales were driven by the antiviral treatment’s launch in the U.S., which has ordered 20 million courses. The Food and Drug Administration authorized Paxlovid in December.

Pfizer reaffirmed its full-year 2022 guidance of $32 billion in Covid vaccine sales and $22 billion for Paxlovid. CEO Albert Bourla had told analysts earlier this year that revenue from its antiviral treatment could come in higher because estimates are based only on deals signed or those close  to finalization. 

Paxlovid is an effective treatment for people who have Covid, but it does not prevent infection. Paxlovid reduced the risk of hospitalization or death from Covid by 90% in a clinical trial of adults who caught the virus and were at high risk of developing severe illness. However, it failed to prevent infection in separate trial results published Friday by Pfizer. 

Pfizer’s vaccine is the most administered Covid shot in the U.S. and the European Union. In the U.S., everyone age 5 and older is eligible for at least a primary series of two doses.

Pfizer is submitting data to the FDA on its three-dose vaccine for children under 5 years old, the only age group left in the U.S. that is not yet eligible for a shot. Bourla, in a podcast interview, said he hopes the vaccine for younger kids will receive authorization in June. The FDA had originally sought to authorize the first two doses in February, but Pfizer postponed its application because the data wasn’t good enough. Bourla has said a third dose should significantly increase protection for the youngest children. 

Pfizer also recently asked the FDA to authorize a third dose for children ages 5 to 11, the only age group eligible for vaccination that cannot yet receive a booster shot in the U.S.

CNBC Health & Science

Read CNBC’s latest global coverage of the Covid pandemic:

  • Trending
  • Comments
  • Latest
HogwartsLegacy dGg671zfMk - TodayHeadline

Hogwarts Legacy: How to open eye chests

283f83ea3518878d0b02aab7ca984181 - TodayHeadline

LeBron James breaks all-time NBA point-scoring record, passing Lakers legend Kareem Abdul-Jabbar

ai used to discover cl 1 scaled - TodayHeadline

AI used to discover clean energy materials ‘faster and more efficiently’

ReserveBlocks RBX token is now live on BitMart Exchange - TodayHeadline

ReserveBlock’s RBX token is now live on BitMart Exchange

PopularStories

HogwartsLegacy dGg671zfMk - TodayHeadline
Gaming

Hogwarts Legacy: How to open eye chests

283f83ea3518878d0b02aab7ca984181 - TodayHeadline
breaking news today

LeBron James breaks all-time NBA point-scoring record, passing Lakers legend Kareem Abdul-Jabbar

ai used to discover cl 1 scaled - TodayHeadline
Technology News

AI used to discover clean energy materials ‘faster and more efficiently’

ReserveBlocks RBX token is now live on BitMart Exchange - TodayHeadline
Finance News

ReserveBlock’s RBX token is now live on BitMart Exchange

About Us

Todayheadline the independent news and topics discovery
A home-grown and independent news and topic aggregation . displays breaking news linking to news websites all around the world.

Follow Us

Latest News

HogwartsLegacy dGg671zfMk - TodayHeadline

Hogwarts Legacy: How to open eye chests

283f83ea3518878d0b02aab7ca984181 - TodayHeadline

LeBron James breaks all-time NBA point-scoring record, passing Lakers legend Kareem Abdul-Jabbar

ai used to discover cl 1 scaled - TodayHeadline

AI used to discover clean energy materials ‘faster and more efficiently’

HogwartsLegacy dGg671zfMk - TodayHeadline

Hogwarts Legacy: How to open eye chests

283f83ea3518878d0b02aab7ca984181 - TodayHeadline

LeBron James breaks all-time NBA point-scoring record, passing Lakers legend Kareem Abdul-Jabbar

ai used to discover cl 1 scaled - TodayHeadline

AI used to discover clean energy materials ‘faster and more efficiently’

  • Real Estate
  • Parenting
  • Cooking
  • NFL Games On TV Today
  • Travel and Tourism
  • Home & Garden
  • Pets
  • Privacy & Policy
  • Contact
  • About

© 2023 All rights are reserved Today headline

No Result
View All Result
  • Real Estate
  • Parenting
  • Cooking
  • NFL Games On TV Today
  • Travel and Tourism
  • Home & Garden
  • Pets
  • Privacy & Policy
  • Contact
  • About

© 2023 All rights are reserved Today headline

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.